Published on 18/12/2025
Mastering PSUR/DSUR Templates: Compliance-Ready Guide for Global Pharmacovigilance Reporting
Introduction to PSUR/DSUR Templates and Their Importance
Periodic Safety Update Reports (PSURs) and Development Safety Update Reports (DSURs) are critical pharmacovigilance documents required by regulators worldwide to evaluate the safety profile of pharmaceutical products. PSURs are submitted for marketed products, while DSURs are required during clinical development. Regulators such as the EMA, FDA, and CDSCO mandate these reports in line with ICH E2C (R2) and ICH E2F guidelines.
By 2025, PSUR/DSUR templates have become indispensable tools for ensuring consistent, compliant, and high-quality safety reporting. They guide regulatory affairs and pharmacovigilance teams in structuring reports, reducing errors, and facilitating inspection readiness.
Key Concepts and Regulatory Definitions
Understanding PSURs and DSURs requires clarity on several regulatory definitions:
- PSUR (Periodic Safety Update Report): A structured pharmacovigilance document summarizing safety data for marketed products over a defined reporting period.
- DSUR (Development Safety Update Report): A safety report required annually during the clinical development phase of a drug.
- ICH E2C (R2): International guideline defining content and format of PSURs.
- ICH E2F: International guideline for DSURs, harmonizing safety reporting during development.
- Template: A standardized format (Word, Excel, XML, or e-submission tools) used
These definitions highlight the central role of templates in ensuring harmonized global safety reporting.
Applicable Guidelines and Global Frameworks
PSUR and DSUR templates are aligned with the following frameworks:
- ICH E2C (R2): Defines PSUR structure, content, and submission frequency.
- ICH E2F: Establishes requirements for DSUR content and annual updates during development.
- EMA GVP Module VII: Provides EU-specific guidance for PSUR submissions through the PSUR Repository.
- FDA Safety Reporting Requirements: Align with DSUR principles for IND safety reporting.
- CDSCO NDCTR 2019: Mandates periodic safety reporting in India aligned with ICH guidelines.
This framework demonstrates global convergence toward harmonized safety reporting using templates.
Processes, Workflow, and Submissions
Preparation of PSURs and DSURs using templates follows structured steps:
- Template Selection: Choose validated templates aligned with ICH and regional guidance.
- Data Collection: Aggregate safety data from pharmacovigilance systems, clinical databases, and literature.
- Drafting: Populate templates with structured data, narratives, and risk assessments.
- Internal Review: Medical, safety, and regulatory experts review draft reports.
- Submission: File via electronic portals such as EMA PSUR Repository, FDA ESG, or CDSCO SUGAM.
- Follow-Up: Address regulator queries or requests for additional safety information.
This workflow ensures timely and compliant submissions while reducing administrative burden.
Sample PSUR Template Structure
A typical PSUR template includes the following sections:
| Section | Content |
|---|---|
| Introductory Information | Product name, reporting interval, company details |
| Worldwide Marketing Authorization Status | Current approvals across regions |
| Update on Safety Actions | Changes to labeling, recalls, or warnings |
| Cumulative Safety Data | Adverse event trends and aggregated safety information |
| Benefit-Risk Evaluation | Assessment of safety vs. efficacy |
| Conclusion | Summary and proposed risk management actions |
Templates ensure completeness, consistency, and compliance with regulatory expectations.
Sample DSUR Template Structure
A DSUR template is tailored for investigational products under development:
| Section | Content |
|---|---|
| Introduction | Study identifiers, reporting interval, sponsor details |
| Worldwide Development Status | Clinical development status across regions |
| Safety Information | Summary of SAEs, SUSARs, and aggregate safety data |
| Benefit-Risk Assessment | Evaluation of safety findings in context of development stage |
| Summary Tables | Tabulated data on cumulative safety reports |
These templates guide sponsors in producing structured and regulator-ready DSURs.
Tools, Software, or Templates Used
Pharmacovigilance teams rely on specialized tools for PSUR/DSUR preparation:
- Word/Excel Templates: Widely used for drafting and formatting PSUR/DSURs.
- Safety Databases: Argus, ArisG, and MedDRA coding tools for case aggregation.
- Publishing Tools: eCTD publishing software for electronic submissions.
- PSUR Repository: EMA platform for centralized EU PSUR submissions.
- Document Management Systems: Veeva Vault, MasterControl for controlled drafting, approvals, and versioning.
These tools reduce errors, enable standardization, and ensure compliance with inspection expectations.
Common Challenges and Best Practices
PSUR/DSUR preparation faces common challenges:
- Data Integration: Aggregating safety data from multiple systems and geographies.
- Timeliness: Meeting strict reporting deadlines within 60 or 90 days.
- Consistency: Aligning narratives, tables, and risk assessments across reports.
- Global Variability: Different submission formats across FDA, EMA, and CDSCO.
Best practices include establishing template libraries, automating data extraction from safety systems, training staff on ICH E2C/E2F requirements, and conducting internal audits of draft reports. Mock inspections ensure reports are inspection-ready.
Latest Updates and Strategic Insights
By 2025, PSUR/DSUR reporting reflects evolving regulatory priorities:
- Digital Submissions: Regulators mandating eCTD format for safety reports.
- AI & Automation: Tools generating safety summaries and tables directly from databases.
- Global Harmonization: ICH Q12 integration promoting alignment of PSUR/DSUR lifecycle reporting.
- Diversity Reporting: Safety reports now require demographic analysis of adverse events.
- Inspection Focus: Regulators scrutinize templates, consistency, and benefit-risk assessments during audits.
Strategically, companies must invest in template-driven pharmacovigilance processes. Those who embed automation, global harmonization, and inspection readiness into safety reporting will achieve faster approvals and higher regulatory trust.
Conclusion
PSUR/DSUR templates are essential for regulatory compliance and patient safety. By following ICH E2C/E2F guidance, leveraging digital tools, and adopting best practices, sponsors can ensure accurate, consistent, and timely safety reporting. In 2025 and beyond, effective use of templates will remain the cornerstone of pharmacovigilance excellence and regulatory confidence.